{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acetate&page=7",
    "query": {
      "intervention": "acetate",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 1448,
    "total_pages": 145,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acetate&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acetate&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T04:36:25.546Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01451424",
      "title": "Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Fibroids"
      ],
      "interventions": [
        {
          "name": "Proellex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "47 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 47 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2012-02",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-08-29",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 2,
      "location_summary": "Miami Gardens, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Miami Gardens",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01451424"
    },
    {
      "nct_id": "NCT01218659",
      "title": "Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "migalastat hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "agalsidase",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "16 Years to 74 Years"
      },
      "enrollment_count": 68,
      "start_date": "2011-09-08",
      "completion_date": "2015-05-28",
      "has_results": true,
      "last_update_posted_date": "2018-11-01",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Decatur, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218659"
    },
    {
      "nct_id": "NCT00005044",
      "title": "Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Casodex",
          "type": "DRUG"
        },
        {
          "name": "Eulexin",
          "type": "DRUG"
        },
        {
          "name": "LHRH agonist",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 1579,
      "start_date": "2000-02",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 241,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005044"
    },
    {
      "nct_id": "NCT04829344",
      "title": "A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anesthesia, Local"
      ],
      "interventions": [
        {
          "name": "AG-920",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Genomics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2021-03-30",
      "completion_date": "2021-05-10",
      "has_results": true,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 1,
      "location_summary": "McAllen, Texas",
      "locations": [
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04829344"
    },
    {
      "nct_id": "NCT01979536",
      "title": "Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma",
        "Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma",
        "Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 137,
      "start_date": "2013-11-13",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 154,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01979536"
    },
    {
      "nct_id": "NCT00240253",
      "title": "A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Concord, California • La Jolla, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240253"
    },
    {
      "nct_id": "NCT06054607",
      "title": "Effect of Short-chain Fatty Acids on Aerobic Endurance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aerobic Endurance",
        "Metabolism"
      ],
      "interventions": [
        {
          "name": "High-amylose maize starch+acetate/butyrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low-amylose maize starch",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "United States Army Research Institute of Environmental Medicine",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "17 Years to 39 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-07-21",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 1,
      "location_summary": "Natick, Massachusetts",
      "locations": [
        {
          "city": "Natick",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06054607"
    },
    {
      "nct_id": "NCT06022939",
      "title": "Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AL Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab and Hyaluronidase-fihj",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Stem Cell Isolation",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2024-07-01",
      "completion_date": "2030-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 117,
      "location_summary": "Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06022939"
    },
    {
      "nct_id": "NCT00469781",
      "title": "Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystoid Macular Edema,",
        "Retinal Thickening"
      ],
      "interventions": [
        {
          "name": "2. Xibrom (Bromfenac)",
          "type": "DRUG"
        },
        {
          "name": "1. Pred Forte",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center For Excellence In Eye Care",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2007-05",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2008-09-25",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00469781"
    },
    {
      "nct_id": "NCT00398528",
      "title": "An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Glatiramer acetate, (Copaxone®)",
          "type": "DRUG"
        },
        {
          "name": "IFN-β-1a, (Avonex®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurognostics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2006-09",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-10-31T04:36:25.546Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Seattle, Washington • Madison, Wisconsin + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398528"
    }
  ]
}